Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Core Insights - Acumen Pharmaceuticals is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody targeting soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD) [7][9] - The company will present scientific findings at two major conferences: the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) and the American Academy of Neurology (AAN) Annual Meeting [1][2] Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease, specifically targeting toxic soluble AβOs, which are implicated in the neurodegenerative process [9] - The company is headquartered in Newton, Massachusetts, and has a strong scientific foundation in AβO research [9] Clinical Trials - The ongoing Phase 2 clinical trial, ALTITUDE-AD, aims to evaluate the efficacy and safety of sabirnetug in slowing cognitive and functional decline in early Alzheimer's disease patients [8] - Approximately 540 individuals with early Alzheimer's disease are expected to be enrolled in this multi-center, randomized, double-blind, placebo-controlled study [8] Upcoming Presentations - Acumen will present oral and poster presentations at the AD/PD conference in Vienna and the AAN Annual Meeting in San Diego, focusing on the use of plasma pTau217 assays and the effects of sabirnetug on synaptic biomarkers [2][3][4] - Specific presentation details include the ALTITUDE-AD study and the early effects of sabirnetug treatment on synaptic biomarkers [3][4][5][6]